Agenda item 4.1 Draft proposal - Notifications of the location of the Pharmacovigilance System Master File (PSMF)
|
|
- Russell Green
- 6 years ago
- Views:
Transcription
1 EMA Implementation Working Group with EU Pharmaceutical Industry Associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) 726/2004 Agenda item 4.1 Draft proposal - Notifications of the location of the Presented by: Ilaria Del Seppia Data Collection and Management Section 5 December 2012 An agency of the European Union
2 In accordance with the Commission s implementing regulation, chapter I, Article 4, paragraph 4 and without prejudice to the requirements set out in Regulation (EC) No 1234/2008, the marketing authorisation holders shall notify immediately the Agency of any change in the location of the pharmacovigilance system master file (PSMF). A change in the location of the PSMF should be notified by the marketing authorisation holder to the Agency within 30 calendar days from the date when the change becomes effective (closure of the variation procedure see presentation agenda item 6). 1
3 For the use of the applicable operation type, please refer to presentation for agenda item 6. 2
4 Pharmacovigilance System Master File Location EVCODE (PSMFL EVCODE) Scenarios * a. Different global company (HQ) b. Same global company (HQ) and different affiliates a. Different global company (HQ) b. Same global company (HQ) and different affiliates MAH Same Different Different Same Different Different Same Different Same Location Same Same Same Same Same Same Different Different Different PV SYSTEM Same Same Same Different Different Different Different Different Same EVCODE to request 1 >1 1 >1 >1 >1 >1 >1 1 COMMENT FIELD List internal PV SYSTEM CODE List internal PV SYSTEM CODE List internal PV SYSTEM CODE List internal PV SYSTEM CODE List internal PV SYSTEM CODE List internal PV SYSTEM CODE List internal PV SYSTEM CODE List internal PV SYSTEM CODE List internal PV SYSTEM CODE Handling of Location Scenarios * Only applicable to variation affecting the location of the PSMF whilst the MAH and the PV System remain the same. 3
5 Handling of Location Scenarios 4
6 The PSMF definition is provided in Article 1(28e) of Directive /83/EC and the minimum requirements for its content and maintenance are set out in the Commission Implementing Regulation (EU) No 520/2012 on the Performance of Pharmacovigilance Activities Provided for in Regulation (EC) No 726/2004 and Directive 2001/83/EC. The detailed requirements provided by the Commission Implementing Regulation are further supported by the guidance in Module II of the Good Vigilance Practice(s) (GVP). The PSMF shall be located either at the site in the EU where the main pharmacovigilance activities of the marketing authorisation holder are performed or at the site in the EU where the qualified person responsible for pharmacovigilance operates [IM Art 7(1)].
7 At the time of marketing authorisation application, the applicant should submit electronically the PSMF location information using the agreed format as referred to in chapter IV, Article 26, paragraph 1(a) of the Commission Implementing Regulation (EU) No 520/2012, and subsequently include in the application, the PSMF reference number, which is the unique code assigned by the Eudravigilance (EV) system to the master file when the XEVPRM is processed. On grant of a marketing authorisation application, the PSMF will be linked by the marketing authorisation holder to the EVMPD product code(s). 6
8 To request an EVCODE for a PSMF, the following three characteristics need to be taken into account: i. The marketing authorization holder (MAH) as a legal entity ii. The location of the PSMF iii. The Pharmacovigilance System (PS) The following case scenarios provide explanations, as to when and how a EVCODE for a PSMF needs to be requested: 7
9 Scenario 1: MAH A has a PSMF location D for the PV system X and therefore requests one EVCODE. The internal code for PV system X should be specified in the comments field (MF 11) by MAH A for the medicinal products applicable. 8
10 Scenario 2a: MAH A and MAH B are different legal entities belonging to different global companies. MAH A and B share the same PV system Y at the same location R. Both MAH A and MAH B request a separate EVCODE. The internal code for PV system Y should be specified in the comments field (MF 11) by the MAH A and by MAH B for the medicinal products applicable. 9
11 Scenario 2b: MAH A and MAH B are different legal entities belonging to the same global company. MAH A and B share the same PV system Y at the same location R. Both MAH A and MAH B share the same EVCODE. The internal code for PV system Y should be specified in the comments field (MF 11) by the MAH A and by MAH B for the medicinal products applicable. 10
12 Scenario 3: MAH A has two different PV systems Y and Z, each with a separate PSMF in the same location R. MAH A therefore requests a separate EVCODE for the PV System Y and corresponding PSMF at location R and for the PV System Z and corresponding PSMF at location R. The internal code for PV systems Y and Z should be specified in the comments field (MF 11) by the MAH A for the medicinal products applicable. 11
13 Scenario 4a: MAH A and MAH B are different legal entities belonging to different global companies. MAH A and B have different PV systems Y and Z at the same location R. Both MAH A and MAH B request a separate EVCODE. The internal code for PV system Y should be specified in the comments field (MF 11) by MAH A and for PV system Z by MAH B for the medicinal products applicable. 12
14 Scenario 4b: MAH A and MAH B are different legal entities belonging to the same global company. MAH A and B have different PV systems Y and Z at the same location R. Both MAH A and MAH B request a separate EVCODE. The internal code for PV system Y should be specified in the comments field (MF 11) by MAH A and for PV system Z by MAH B for the medicinal products applicable. 13
15 Scenario 5: MAH A has two different PV systems Y and Z, each with a separate PSMF in two locations R and S. MAH A therefore requests a separate EVCODE for the PV System Y and corresponding PSMF at location R and for the PV System Z and corresponding PSMF at location S. The internal code for PV system Y and Z should be specified in the comments field (MF 11) by MAH B for the two corresponding EVCODEs. 14
16 Scenario 6: MAH A has a PSMF at location D for one PV system X; MAH B has a PSMF at location E for one PV system Z. Therefore MAH A and MAH B each request a separate EVCODE. The internal code for PV system X should be specified in the comments field for the EVCODE by MAH A. The internal code for PV system Z should be specified in the comments field by MAH B. The internal code for PV system X should be specified in the comments field (MF 11) by MAH A. The internal code for PV system Z should be specified in the comments field (MF 11) by MAH B. 15
17 Scenario 7: Only applicable to variation affecting the location of the PSMF whilst the MAH and the PV System remain the same. In this scenario the PSMF location should be updated to reflect the change in the location but the PSMF EVCode shall be maintained. Submission of the summary of the pharmacovigilance system information to competent authorities to fulfil the requirement of Article 8(3) of the Directive 2001/83/EC (and within XEVMPD), cannot contain multiple locations for a single pharmacovigilance system master file (PSMF). The PSMF location declared should be an office address which reflects either the site in the Union where the main pharmacovigilance activities of the marketing authorisation holder are performed or the site in the Union where the qualified person responsible for pharmacovigilance operates. 16 [References: Commission implementing regulation No 520/2012, Article 7 (1), Directive 2001/83/EU, Article *(3), GVP Module II (II.B.3)]
18 Scenario 7: Only applicable to variation affecting the location of the PSMF whilst the MAH and the PV System remain the same. In this scenario the PSMF location should be updated to reflect the change in the location but the PSMF EVCode shall be maintained. MAH A has a PSMF at location D for one PV system X; MAH A change only the location of the PV system X from location D to location Z. MAH A should submit an XEVPRM with operation type Update of the relevant PSMFL EVCode with the change of the location from D to Z. 17
19 Please refer also to the Question and Answers on transitional arrangements concerning the entering into force of the New Pharmacovigilance Rules provided by Directive 2010/84/EU amending Directive 2001/83/EC and Regulation (EU) No 1235/2010 amending Regulation (EC) No 726/2004 as well as the Questions and answers on practical transitional measures for the implementation of the pharmacovigilance legislation. 18
20 Discussion 19
PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector
PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted
More informationData quality control methodology for data submitted under Article 57(2) of Regulation (EC) No.726/2004
5 April 2018 EMA/227883/2014, Rev. 2 1 Information Management Data quality control methodology for data submitted under Article 57(2) of Regulation (EC) 1 MDMS contact point was replaced with EMA Service
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationFormat and content of electronic periodic safety update reports (Technical contribution to EC implementing measure)
Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure) First Stakeholders Forum on the implementation of the new Pharmacovigilance legislation,
More informationIntroductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update Reports
24 October 2016 EMA/606369/2012 Rev.15 Procedure Management and Committees Support Introductory cover note to the List of European Union reference dates and frequency of submission of Periodic Safety Update
More informationEudraVigilance auditable requirement project
22 November 2017 EMA/835422/2016 Information Management Division EudraVigilance training plan (version 5) Project Maintenance Group 1 consultation 11 December 2015 Eudravigilance Expert Working Group consultation
More informationFourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation
Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation Module II - Pharmacovigilance system master file Presented by: Joanna Harper Inspections, Enforcement & Standards
More informationPharmacovigilance. An agency of the European Union
Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related
More informationNew EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change
New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change Training Module PhV-M1 Overview of legal provisions that form the basis for the new EudraVigilance functionalities
More informationMircea Ciuca, MD Global Head Medical & Clinical Drug Safety
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,
More informationSafety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationPharmacovigilance: Information systems and services
Pharmacovigilance: Information systems and services Supporting business activities of the revised pharmacovigilance legislation through better information systems An agency of the European Union To deliver
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 14 December 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4
More informationQuestions And Answers To Support The
Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation
More informationExplanatory note on general fees payable to the European Medicines Agency
Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation
More informationCMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES
CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES 1. INTRODUCTION (BACKGROUND) November 2007 According to Article 8
More informationExplanatory Note to GVP Module VII
31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure
More informationInterdependencies of Pharmacovigilance and Regulatory Affairs
Lorenz userbridge 2013 Budapest, September 17th Interdependencies of Pharmacovigilance and Regulatory Affairs Dr. rer. nat. Markus Dehnhardt Deputy QPPV Biologist Toxicologist Medical advisor Agenda 1.
More informationClinical Trial Safety Reporting requirements
Clinical Trial Safety Reporting requirements SME info day 20 Mar 2017 Presented by Sophia Mylona Clinical & Non-clinical Compliance, European Medicines Agency An agency of the European Union Article Regulation
More informationINTRODUCTION OF FEES TO BE CHARGED BY THE EMA FOR PHARMACOVIGILANCE
Ref. Ares(2012)723154-18/06/2012 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, D(2012) INTRODUCTION OF FEES TO
More informationQ/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008
Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008 1. General questions Doc. Ref: CMDh/132/2009/Rev.20 May 2013 Question 1.1 What is the definition of MAH? According
More informationEMA pharmacovigilance system manual
13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000
More informationSafety Measures in the new Pharmacovigilance System
Safety Measures in the new Pharmacovigilance System Dr. Harald Tietz Director Global Patient Safety & Regulatory Affairs, Germany Lilly Deutschland GmbH Documentation and reporting requirements: Centralisation
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012
More informationDi Renzo Regulatory Affairs ROME - MILAN - LONDON
Di Renzo Regulatory Affairs ROME - MILAN - LONDON Di Renzo Regulatory Affairs In 1985, Di Renzo Regulatory Affairs began its regulatory consulting for medicines for human and veterinary use, food and dietary
More informationEudraVigilance access policy for medicines for human use
23 August 2011 EMA/759287/2009 corr. Patient Health Protection Draft agreed by the EudraVigilance Expert Working Group December 2007 Consultation with the EudraVigilance Steering Committee February 2008
More informationGENERAL AND ORGANISATIONAL REQUIREMENTS
NBOG working document applicable for MDR and IVDR WD 2017-1 Draft list of documents to be submitted in the application for designation as a notified body under Regulation (EU) 2017/745 and Regulation (EU)
More informationMedical Literature Monitoring
Medical Literature Monitoring 5 th Industry Platform on the implementation of EU pharmacovigilance legislation Presented by Tom Paternoster-Howe on 15 September 2015 EMA/Information Management/Data Standardisation
More informationGuideline on the processing of renewals in the centralised procedure
22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation
More informationIntroduction to the Identification of Medicinal Products ( IDMP)
Content Introduction to the Identification of Medicinal Products ( IDMP)... 2 What is the legal base for IDMP?... 2 Who is affected by IDMP?... 2 Current regulations in the US and Europe... 2 Implications
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/827661/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming into effect of first version 2 July 2012 Draft Revision 1* finalised
More informationFergus Sweeney, European Medicines Agency
Fergus Sweeney, European Medicines Agency Disclaimer The views presented in this presentation/these slides are those of the author and should not be understood or quoted as being made on behalf of the
More informationUpdate ICSR Reporting. EudraVigilance Reporting Getting ready for E2B (R3) Disclaimer:
Update ICSR Reporting Dr. Waltraud Trabe / Mag. Katharina Weber Austrian Federal Office forsafety in Healthcare Institute of Surveillance Dep. BTVI (Blood, Tissue & Vigilance) Traisengasse5, 1020 Vienna
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationDoc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021
National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda Tel: 256-0414 - 255665/347391/2 E-mail: ndaug@nda.or.ug Website: http://www.nda.or.ug Doc. No. DPS/GDL/034
More informationEuropean Medicines Agency post-authorisation procedural advice for users of the centralised procedure
11 December 2017 EMEA-H-19984/03 Rev. 75 Human Medicines Evaluation Division European Medicines Agency post-authorisation procedural advice for users of the This integrated version has been created for
More informationRSC/CT Det. no. 1/2013
RSC/CT Det. no. 1/2013 Protocol 1631-P The English version of this Determination was prepared in order to help comprehension by non-italian mother tongue users, but is NOT an official document. Please
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE
More informationPharmacovigilance Legislation: The Impact of What Is Happening in Europe
Miranda Z. Dollen, BSc (Hons) 1 Abstract Pharmaceutical companies, regulatory agencies, and contract service organizations are managing substantial and ongoing changes to pharmacovigilance legislation
More informationFMD Workshop 27 June 2016
FMD Workshop 27 June 2016 Meeting outcome Presented by Paolo Alcini Head of Data Standardisation and Analytics Service An agency of the European Union Point Discussed during the WS Review of draft agenda
More informationChapter 3.II: XEVPRM User Guidance. Version Version number: Published: Date of coming into force: Version 3.12 April May 2017
19 April 2017 EMA/135580/2012 Information Management Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European
More informationCP ON DRAFT GL ON SUPPORT MEASURES EBA/CP/2014/17. 9 July Consultation Paper
EBA/CP/2014/17 9 July 2014 Consultation Paper Draft Guidelines On the types of tests, reviews or exercises that may lead to support measures under Article 32(4)(d)(iii) of the Bank Recovery and Resolution
More informationPharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010
Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010 Content Legal basis What do agencies want? What happens Before During After How do you
More informationGood Vigilance Practice Modules I-IV PV quality assurance and control
Good Vigilance Pracice Modules I-IV PV qualiy assurance and conrol Fergus Sweeney, PhD, European Medicines Agency Head, Compliance and Inspecions EU 28: Science, Medicines, Healh Dubrovnik, Croaia, 6-7
More informationUpdate on EMA Brexit preparedness
Update on EMA Brexit preparedness SME Office Info Day on Supporting innovative medicines development and early access 17 November 2017 Presented by Anthony Humphreys An agency of the European Union EMA
More informationarena that impact on clinical development
RESEARCH DEVELOPMENT Changes in the regulatory arena that impact on clinical development 23 May 2011 Agenda Voluntary Harmonisation Procedure PIP and Paediatric requirements Changes to EudraCT and European
More informationFunctioning of the PRAC
Functioning of the PRAC Sixth Stakeholders forum on the implementation of the new Pharmacovigilance legislation, November 8 th 2012 Presented by: Almath Spooner Vice Chair, Pharmacovigilance Risk Assessment
More informationReport to the European Commission on Pharmacovigilance audits carried out in the Bulgarian Drug Agency period of time from April 2011 to June 2013
Report to the European Commission on Pharmacovigilance s carried out in the Bulgarian Drug Agency period of time from April 2011 to June 2013 1. INTRODUCTION This report provides an overview of the s conducted
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES. Draft. COMMISSION REGULATION (EU) No /
EN EN EN COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, C Draft COMMISSION REGULATION (EU) No / of [ ] amending Commission Regulation (EC) No 1702/2003 laying down implementing rules for the airworthiness
More informationEuropean Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
11 December 2017 EMA/821278/2015 Human Medicines Research and Development Support European Medicines Agency pre-authorisation procedural advice for users of the This integrated version has been created
More informationModule 1: Administrative information Application form
7 September 2017 CMDh/332/2017/Rev.1 User guide for the electronic application form for a Marketing Authorisation Purpose and general rules This User guide has been prepared in order to facilitate the
More informationMilan, 7 th June 2012
Milan, 7 th June 2012 PNEUROP Comments on the alignment of 2009/105/CE SPVD Directive with Decision 768/2008 NLF or Goods Package Commission proposal COM(2011) 768 final European Parliament Draft Reports
More informationQUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT
QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT Doc. Ref.: CMDh/274/2012, Rev3 NovemberRev4 December 2012 QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT... 1 Where can guidance and recommendations
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR AGRICULTURE AND RURAL DEVELOPMENT
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR AGRICULTURE AND RURAL DEVELOPMENT Directorate D. Direct support D.2. Greening, cross-compliance and POSEI GUIDANCE DOCUMENT ON THE IMPLEMENTATION BY MEMBER STATES
More informationEuropean Medicines Agency practical guidance on the application form for centralised type IA and IB variations
30 June 2017 EMA/233564/2014 - Rev. 2 Procedure Management and Business Support Division European Medicines Agency practical guidance on the application form for centralised This document is intended as
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/827661/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted
More informationImpact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More informationThe European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications
The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical
More informationon remuneration policies and practices related to the sale and provision of retail banking products and services
EBA/GL/2016/06 13/12/2016 Guidelines on remuneration policies and practices related to the sale and provision of retail banking products and services 1. Compliance and reporting obligations Status of these
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR AGRICULTURE AND RURAL DEVELOPMENT
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR AGRICULTURE AND RURAL DEVELOPMENT Directorate D. Direct support D.2. Greening, cross-compliance and POSEI GUIDANCE DOCUMENT ON THE IMPLEMENTATION BY MEMBER STATES
More informationMonthly statistics report: December 2017
19 January 2018 EMA/39932/2018 Information Management Division Medicinal products for human use (cumulative figures for the year to date) This document provides current information related to the volume
More informationEudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia
EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia Presented by: Vladimir Raketić, DVM, spec; Audit /QM group Ministry of Agriculture, Forestry and Water Managment, Veterinary
More informationMEDICINES CONTROL COUNCIL
MODULE 1 1.2.1 MEDICINES CONTROL COUNCIL APPLICATION FOR REGISTRATION OF A MEDICINE 1 Module 1: Administrative Information Application Form This application form will be included in the South African Common
More informationEphMRA Adverse Event Reporting Guidelines 2016
EphMRA Adverse Event Reporting Guidelines 2016 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European
More informationEudraVigilance Veterinary
15 September 2011 EMA/13787/2009 STATUS REPORT TO EMA MANAGEMENT BOARD / VETJIG 1 / PHVWP-V 2 / CVMP 3 / HMA-V 4 / CMD-V 5 This document is published on the EVVet Website: http://eudravigilance.ema.europa.eu/veterinary
More information-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009
Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member
More informationEMA/CMDh EXPLANATORY NOTES ON VARIATION APPLICATION FORM (Human medicinal products only)
EMA/CMDh EXPLANATORY NOTES ON VARIATION APPLICATION FORM (Human medicinal products only) Doc. Ref.: CMDh/EMA/133/2010/Rev4 October 2010 INTRODUCTION AND GENERAL COMMENTS This document is intended to provide
More informationQuality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany. Audit No. CT6018. Date of Audit: 3rd to 5th May 2017
Quality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany Head Office Address FGK Clinical Research GmbH Heimeranstrasse 35, 80339 Munich, Germany Research Centre Address FGK Clinical
More informationAgenzia Italiana del Farmaco
Agenzia Italiana del Farmaco European Regulation on Advanced Therapies Cristina Pintus Head of European Relations Unit and Coordinator of the Advanced Therapy Project Italian Medicines Agency Proposal
More informationFrankfurt am Main, Germany
Sponsored by: PV and Vigilance duties and challenges in the practice: Frankfurt am Main, Germany Thursday, May 4th 2017 Lufthansa Flight Training Frankfurt Airportring, Gate 24, Buildings 391 and 392 -
More informationEudraCT database and EU Clinical Trials Register (EU-CTR)
EudraCT database and EU Clinical Trials Register (EU-CTR) Presented by: Laura Pioppo Compliance and Inspection Sector PCWP and HCP WG 16.06.2011 An agency of the European Union Definitions information
More informationOfficial Journal of the European Union. (Acts whose publication is obligatory)
5.11.2003 L 287/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1946/2003 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 15 July 2003 on transboundary movements of genetically modified organisms
More informationProcedure management of variations
Procedure management of variations Process changes made and current challenges Presented by Alberto Ganan and Iordanis Gravanis on 24 April 2015 Procedure Management Department An agency of the European
More informationEuropean Commission s strategy for single market Using Bolar and the SPC Wavier to Stimulate Growth in the EU
European Commission s strategy for single market Using Bolar and the SPC Wavier to Stimulate Growth in the EU Ravinder Chahil Director of Intellectual Property Polpharma Group SA 8 March 2016 Content Commission
More informationA GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline
More informationetmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector
etmf A Regulators Perspective Paula Walker, GCP Operations Manager & Senior GCP Inspector Agenda EU Legislation and Guidance News/Updates relating to TMF Structure and Content of e/tmf Inspecting etmfs
More informationConformity Assessments Revised Toy Safety Directive 2009/48/EC
Toy Safety Update Conformity Assessments Revised Toy Safety Directive 2009/48/EC Contents 1. Obligations of Economic Operators 2. Introduction 3. Overview 4. How to use this guide 5. The Conformity Assessment
More informationAPPLICATION FOR VARIATION TO A MARKETING AUTHORISATION
Page 1 of 13 May 2008 APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION HUMAN VETERINARY NATIONAL AUTHORISATION IN MRP MRP variation number 1A : / / / / / COMMUNITY AUTHORISATION EMEA variation number
More informationAPI EUROPEAN GMP REQUIREMENTS. Alessio Ferrari
API EUROPEAN GMP REQUIREMENTS Alessio Ferrari SUMMARY GUIDELINES IMPLICATIONS FOR THE INDUSTRY ARTICLE 46 (F) OF DIRECTIVE 2001/83/EC PART I EU GMP Chapter 5 OFFICIAL MEASURES TO PROTECT. PROCEDURE TO
More informationTrack III: International Clinical Trials: Global Compliance Norms and EU Focus
Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health
More informationA practical guide to achieving and maintaining global oversight and ensuring end-to-end pharmacovigilance
FOR PHARMA & LIFE SCIENCES WHITE PAPER A practical guide to achieving and maintaining global oversight and ensuring end-to-end pharmacovigilance The increasing complexity of today s pharmaceutical industry
More informationGUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES
MDEG - 2007-12 - II-3.3 MSOGClassIGuidance_Final GUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES Foreword These guidance notes do not aim to be a definite interpretation of National Laws and/or
More informationCouncil Directive 98/59/EC of 20 July 1998 on the approximation of the laws of the Member States relating to collective redundancies
Council Directive 98/59/EC of 20 July 1998 on the approximation of the laws of the Member States relating to collective redundancies Official Journal L 225, 12/08/1998 P. 0016-0021 THE COUNCIL OF THE EUROPEAN
More informationANNEX XIV COMPETITION
27.10.2017 - EEA AGREEMENT - ANNEX XIV p. 1 ANNEX XIV COMPETITION TABLE OF CONTENTS A. Merger Control B. Vertical Agreements and Concerted Practices C. Technology Transfer Agreements D. Specialization
More informationDRAFT OPINION. EN United in diversity EN. European Parliament 2017/0035(COD)
European Parliament 2014-2019 Committee on Environment, Public Health and Food Safety 8.12.2017 2017/0035(COD) DRAFT OPINION of the Committee on the Environment, Public Health and Food Safety for the Committee
More information10972/14 IV/NC/kp DGB 2
Council of the European Union Brussels, 11 July 2014 (OR. en) Interinstitutional File: 2010/0208 (COD) 10972/14 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: AGRI 445 V 621 AGRILEG 130 DLEG 108 MI 496
More informationSPOR data management services - high level changes
6 July 2017 EMA/551661/2016 version 3 Information Management Division Table of contents 1. Introduction... 2 2. New solutions for access and use of SPOR data... 2 2.1. RMS backward compatibility... 2 2.2.
More informationFinnish Medicines Agency Administrative Regulation PHARMACOVIGILANCE
Administrative regulation 22.5.2013 3427/03.01.01/2012 4/2013 UNOFFICIAL TRANSLATION Finnish Medicines Agency Administrative Regulation PHARMACOVIGILANCE Legal basis Section 30 c subsection 3, section
More informationCOMMISSION DELEGATED REGULATION (EU) No /.. of
EUROPEAN COMMISSION Brussels, 4.3.2014 C(2014) 1332 final COMMISSION DELEGATED REGULATION (EU) No /.. of 4.3.2014 supplementing Directive 2013/36/EU of the European Parliament and of the Council with regard
More informationEffective from 18th January RINA Services S.p.A. Via Corsica Genova - Italia
Rules for EC Certification of Recreational Craft and Components, Personal Watercraft, Noise Emissions from Recreational Craft and Exhaust Emissions from Propulsion Engines. Effective from 18th January
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationEMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9).
EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9). Responsible, under the Head of Unit for the Post-Authorisation Evaluation of Medicinal Products
More informationVariations AGES MEA-LCM-QUAL. Mag. Caroline Kleber. Meet the Case Manager Vienna,
Mag. Caroline Kleber Meet the Case Manager Vienna, 9. 11. 2017 AGES MEA-LCM-QUAL Regulatory Background Commission Regulation (EC) No 1234/2008, amended by No 712/2012 Guidelines of 16.05.2013 on the details
More informationDirector of Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Provisional translation (as of March 27, 2008) 1 PFSB / ELD Notification No. 0210004 February 10, 2005 *Revised in accordance with PFSB / ELD Notification No. 0619004 June 19, 2007 Director of Evaluation
More information